ASX pot-stock RotoGro scores $2.3M order

|

Published 04-APR-2018 12:30 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

RotoGro World Wide (Canada) Inc., a wholly-owned subsidiary of RotoGro International Limited (ASX:RGI), has secured a $2.3 million order from Miracle Valley Medical Alternatives M.V.M.A. Ltd., a Health Canada licensed producer.

RGI is an Australian-based company with licensed, proprietary, patented and patents-pending technology in the stackable rotary hydroponic garden space. It also holds worldwide exclusive licenses for legalised medicinal and recreational cannabis markets, as well licences as for all other purposes including pharmaceuticals, health and nutrition supplements, nutraceuticals and perishable foods.

Miracle Valley is currently building a 29,000 square foot state-of-the-art cultivation and manufacturing facility in British Columbia, Canada.

Phase one of the facility comprises some 10,000 square feet of grow rooms outfitted with RotoGro Hydroponic Garden Systems, to be stacked two units high and in four-unit pods, complete with the RotoGro propriety iGrowTM software grow management system.

Miracle Valley projects that the facility will produce up to 12,000 lbs (5,400 kilograms) of legal cannabis per year, harnessing RGI’s leading-edge patented and patent-pending designs, which provide the lowest cost per gram and the highest yield per square foot in the industry.

This order is the culmination of several months of collaboration, whereby RGI provided Miracle Valley with front-end technical support and facility design solutions across the spectrum of building selection, electrical and mechanical design, liaison with local municipalities, installation specifications, and building layout and optimisation.

As part of the order, RGI will provide onsite assembly, installation, testing, certification, training and growing management support.

It’s worth noting here that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.

RGI managing director, Michael Carli, said: “The successful award of the Miracle Valley order is a major milestone in RotoGro’s quest to becoming the world leader in hydroponic agricultural technology.”

“The order provides the company with its first large-scale Health Canada Licensed Producer, which will be a flagship to promote further large-scale orders of our RotoGro Hydroponic Garden Systems.”

“Currently, there are 93 Health Canada Licensed Producers in Canada with a further 208 applicants in the final stage of the Health Canada licensing process,” Carli noted. “Our RotoGro team has been working diligently with numerous prospective clients, and the award of the Miracle Valley order is a testament to their ongoing efforts from initial enquiry to securing the order.”

“We will continue targeting and working with lawful cannabis cultivators and perishables growers to nurture our sales pipeline for future orders. Each inquiry brings unique technical support and design needs which require our team to remain solution and outcome oriented in order to provide the most suitable solution for our customers,” Carli added.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X